TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsVanda's experimental COVID-19 drug shows promise in interim trial data
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
This handout illustration image obtained February 27, 2020 courtesy of the US Food and Drug Administration shows the COVID-19.COVID-19 patients with pneumonia improved faster when treated with Vanda Pharmaceuticals Inc's experimental therapy than those on placebo, the company said on Tuesday, citing an interim analysis of data from a late-stage study. (AFP/Handout / US Food and Drug Administration)
C
OVID-19 patients with pneumonia improved faster when treated with Vanda Pharmaceuticals Inc's experimental therapy than those on placebo, the company said on Tuesday, citing an interim analysis of data from a late-stage study.
Shares of the US drug developer rose over 13% before the opening bell.
While the data from 60 patients showed that a 14-day treatment with the drug, tradipitant, helped speed up clinical improvements by day seven, the company warned a larger patient size was needed to confirm the benefit.
So far, Gilead Sciences Inc's antiviral remdesivir and the generic steroid dexamethasone have been shown to help patients with COVID-19 in rigorous clinical trials.
The US drug developer, which licensed tradipitant from Eli Lilly and Co in 2012, eventually plans to enroll 300 patients in the late-stage trial.
The US Food and Drug Administration (FDA) has imposed a partial clinical hold on tradipitant trials that are longer than 12 weeks, citing the need for additional studies before testing the drug in humans beyond that timeframe. A US court sided with the FDA in January over a legal dispute related to the agency's decision.
The drug is also being tested as a treatment for various conditions including atopic dermatitis and motion sickness. The company says the drug targets a receptor in the body that could be associated with causing lung injury.
Vanda said the drug's properties as an anti-inflammatory agent would complement antiviral drugs for COVID-19, if the results from its analysis were confirmed.
